A Phase 2a Randomized, Double Blind, Placebo Controlled, Single-center Study of ST266 Spray in Diabetic Subjects With Deep Burns Managed With Meshed Skin Grafts.
Overview
- Phase
- Phase 2
- Intervention
- ST266
- Conditions
- Third Degree Burns
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Safety
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns. The secondary objectives of this study are to (1) evaluate efficacy of ST266 in healing burns and (2) evaluate whether treatment with ST266 results in less scarring, in subjects with diabetes separately comparing healing of the skin graft and the skin graft donor site using ST266 plus a burn dressing versus placebo and a burn dressing.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed and dated Institutional Review Board-approved written Informed Consent
- •18 - 75 years of age.
- •Thermal or scald burn, either full thickness or deep partial thickness, which in the opinion of the burn surgeon, requires a meshed skin graft to heal.
- •Target burn area for treatment equal to or less than three percent total body surface area.
- •A skin graft site harvested at 10/1000ths of an inch and a skin graft meshed at 2:
- •Total Body Surface Area (TBSA) burn of less than or equal to 20 percent total body surface.
- •Patient must have a known history of diabetes, or be found to have diabetes at the time of admission, confirmed by a Hemoglobin A1C of greater than 6.5 percent.
- •If a woman of child-bearing potential (WOCBP), she and her partner must be willing to employ either a highly effective form of birth control (e.g., implants, injectable medications, a hormone combination oral contraceptive, etc.), sexual abstinence, or a vasectomised partner, in combination with a barrier method, for the entire duration of the study (through study discharge). Male subjects with a WOCBP partner must be willing to use a condom during sexual activity for the entire duration of the study (through study discharge).
- •Willing to participate in the clinical study and comply with the requirements of the trial.
Exclusion Criteria
- •Full thickness burns involving tendon, ligament, bone, or joint capsule.
- •Burns of the face, neck, palmer surface of the hands and plantar surface of the foot.
- •Burn from chemical, electrical or radiation causes.
- •Subjects with any immune deficiency including current treatment with corticosteroid medication, chemotherapeutic agents, anti-viral therapy, or concurrent radiation therapy within 30 days of signing the informed consent.
- •Active cancer or a history of cancer in the five years prior to signing the informed consent form. (History of basal cell carcinoma is allowed).
- •Life expectancy of less than one year.
- •Patients requiring care in the Intensive Care Unit.
- •Inhalation injury requiring mechanical ventilation.
- •Multiple trauma (significant traumatic injury to a solid organ in addition to skin).
- •Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to subject compliance.
Arms & Interventions
ST266
ST266 sprayed to the skin graft and donor site
Intervention: ST266
Saline
Saline (placebo)sprayed to the skin graft and donor site
Intervention: Saline
Outcomes
Primary Outcomes
Safety
Time Frame: Beginning at enrollment and continuing 12 months after last treatment
The primary objective of this study is to evaluate the safety of ST266 in treating burns in diabetic subjects by evaluating adverse events and serious adverse events. Physical examination, hematology, serum chemistry, urinalysis, vital signs, Adverse Event monitoring, and concomitant medications, cytokine and antibody levels will be monitored at baseline and during the study.
Secondary Outcomes
- Healing of skin graft(Up to 2 weeks of treatment)
- Healing of skin graft donor site(Up to 2 weeks of treatment)
- Scarring of skin graft(One year following treatment)
- Scarring of skin graft donor site(One year following treatment)